Leerink Partnrs Estimates Shattuck Labs Q1 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Shattuck Labs in a research note issued to investors on Thursday, August 14th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.11) per share for the quarter. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Shattuck Labs’ Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS and Q4 2026 earnings at ($0.08) EPS.

Other analysts have also recently issued reports about the company. Leerink Partners cut their price objective on Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Shattuck Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $1.00 on Monday. The stock’s 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $1.01. The stock has a market cap of $47.90 million, a price-to-earnings ratio of -0.83 and a beta of 1.63. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $3.95.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently made changes to their positions in the stock. Bridgeway Capital Management LLC boosted its position in shares of Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after purchasing an additional 55,000 shares in the last quarter. 683 Capital Management LLC boosted its position in shares of Shattuck Labs by 4.3% in the 2nd quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock worth $867,000 after purchasing an additional 45,000 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Shattuck Labs by 2,510.8% in the 2nd quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock worth $229,000 after purchasing an additional 278,576 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Shattuck Labs in the 2nd quarter worth approximately $44,000. Finally, Pinnacle Associates Ltd. boosted its position in shares of Shattuck Labs by 4.9% in the 2nd quarter. Pinnacle Associates Ltd. now owns 1,363,723 shares of the company’s stock worth $1,080,000 after purchasing an additional 64,000 shares in the last quarter. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.